期刊文献+

尼可地尔治疗冠心病慢性心力衰竭疗效观察 被引量:19

Clinical effect of Nicorandil in the treatment of heart failure caused by coronary heart disease
下载PDF
导出
摘要 目的观察尼可地尔治疗冠心病慢性心力衰竭的临床疗效。方法选取在我院住院的冠心病慢性心力衰竭患者228例,随机分成实验组和对照组,对照组予常规治疗,实验组在对照组治疗方案的基础上加用尼可地尔治疗,以1个月为一个疗程,出院后随访观察5个月,观察治疗1个月后两组患者脑钠肽(BNP)值的变化以及随访5个月后左室射血分数(LVEF值)、室间隔厚度(IVS)、左室后壁厚度(LVP)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)的变化。结果实验组BNP值、IVS、LVP、LVEDD、LVESD值较对照组治疗后降低明显,LVEF值较对照组治疗后升高明显(P<0.05)。结论尼可地尔可以治疗冠心病慢性心力衰竭,改善患者症状的心功能。 Objective To observe the clinical effect of Nicorandil on heart failure caused by coronary heart disease.Methods 228 patients of heart failure caused by coronary heart disease were randomly divided into the study group(n=108) and the control group(n=120).Patients in the control group were given conventional treatment,while those in the study group were given Nicorandil on the basis of conventional treatment.The variation of Brain Natriuretic Peptide(BNP) one month after treatment,and left ventricular ejection fraction(LVEF),ventricular septal thickness(IVS),left ventricular posterior wall thickness(LVP),left ventricular end diastolic diameter(LVEDD) and left ventricular end systolic diameter(LVESD) five months after treatment were compared between the two groups.Results Compared with the control group,the decrease of BNP,IVS,LVP,LVEDD and LVESD in the study group after treatment was more significantly(P〈0.05),and the increase of LVEF in the study group was more significantly(P〈0.05).Conclusion Nicorandil can treat heart failure caused by coronary heart disease effectively and improve the cardiac function.
作者 周温
出处 《海南医学》 CAS 2012年第4期18-20,共3页 Hainan Medical Journal
关键词 尼可地尔 冠心病 心力衰竭 脑钠肽 左室射血分数 Nicorandil Coronary heart disease Heart failure Brain natriuretic peptide Left ventricular ejection fraction
  • 相关文献

参考文献5

二级参考文献42

  • 1李新立,卢新政.钾通道激动剂尼可地尔用于高危稳定型心绞痛患者的疗效[J].世界临床药物,2005,26(4):209-211. 被引量:17
  • 2无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量:2052
  • 3Iwai T,Tanonaka K,Motegi K,et al.Nicorandil preserves mitochondrial function during ischemia in perfused rat heart[J].Eur J Pharmacol,2002,446(1-3):119-127.
  • 4Carreira RS,Monteiro P,Kowaltowski AJ,et al.Nicorandil protects cardiac mitochondria against permeability transition induced by ischemia-reperfusion[J].J Bioenerg Biomembr,2008,40(2):95-102.
  • 5Monassier JP.Reperfusion injury in acute myocardial infarction:from bench to cath lab.Part Ⅱ:Clinical issues and therapeutic options[J].Arch Cardiovasc Dis,2008,101(9):565-675.
  • 6Liu J,Long C,Ji B,et al.Myocardial protective effects of nicorandil,an opener of potassium channels on senile rat heart[J].Perfusion,2006,21(3):179-183.
  • 7Hai S,Takemura S,Minamiyama Y,et al.Mitochondrial K(ATP) channel opener prevents ischemia-reperfusion injury in rat liver[J].Transplant Proc,2005,37(1):428-431.
  • 8Olaf O,Michael V,Cohen DM,et al.Mitochondrial KATP channels:role in cardioprotection.Cardiovasc Res,2002,55:429.
  • 9孙传兴.临床疾病诊断依据治愈好转标准[M].2版.北京:人民军医出版社,2006.
  • 10心血管药物对策专题组.心血管药物临床试验评价方法的建议Ⅵ 抗心肌缺血药[J].中华心血管病杂志,1998,26:405-405.

共引文献248

同被引文献120

引证文献19

二级引证文献136

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部